The purpose of this work is to present the results of allogeneic stem cell transplantation as therapy for patients diagnosed with acquired aplastic anemia in the Department of Bone Marrow Transplantation of Fundeni Clinical Institute and to elaborate an algorithm of treatment in aplastic anemia starting with the observations obtained from our clinical practice and following the European treatment guidelines in this group of patients. Aplastic Anemia (AA) is a rare hematological disease characterized by pancytopenia and a hypocellular bone marrow. The paradigm of bone marrow failure syndromes, aplastic anemia is a diagnosis of exclusion despite the precision of its diagnosis criteria. Although AA is not a malignant disease, but an autoimmune disorder, the grave consequences of pancytopenia and clonal transformation into acute leukemia make it a potentially fatal condition.
In children and young adults, acquired AA should be distinguished from the inherited forms of bone marrow failure such as Fanconi's anemia as the differentiation has therapeutic implications. Patients with Fanconi's anemia often have physical anomalies, but the distinction depends on the laboratory finding of abnormal chromosome fragility seen readily in metaphase preparations of peripheral blood lymphocytes cultured with phytohemagglutinin. Chromosomal breakage is strikingly enhanced compared with controls if clastogenic agents, such as diepoxybutane, are added to the culture.
However, in older patients, the major differential diagnosis is between AA and hypoplastic myelodisplastic syndrome which sometimes may be one of the most difficult diagnostic issues. The main differences between these two entities are the absence of dysplasia, splenomegaly, blast cells, marrow fibrosis and cytogenetic anomalies in AA which Other association observed in 5-10% of aplastic anemia cases is with seronegative hepatitis. It is characterized by self-limited liver inflammation, elevated liver enzymes often severe, negative viral serology for hepatitis A, B or C. The post-hepatitis AA typically occurs in young, healthy males and it seems to have a poorer prognosis than idiopathic AA, with early estimates of mortality of 90% at one year, and a history of hepatitis in AA has been considered an indication for early BMT. Patients with posthepatitis AA can successfully undergo BMT without an increased risk of veno-occlusive disease. Patients with hepatitisassociated AA have markers of immune system activation and respond well to intensive immunosuppressive therapy.
Pregnancy is common in the age groups most susceptible to BM failure, and in many cases, its association is probably only coincidental. The true frequency of AA in pregnancy is unknown, but from the number of cases reported, it appears rare, although bone marrow hypoplasia may be relatively common during pregnancy. Survival rates for AA in pregnancy have been relatively high for the mother and baby, with the most pregnancies being successful. The published data are insufficient to guide the management of pregnant women with AA. A woman who desires a child can be maintained with transfusions, as hemorrhage is the most common cause of death from AA during pregnancy.
In a large multicenter study of the Severe AA Working Party of the EBMT the association between aplastic anemia and an autoimmune disease was reported in 50 of 1251 AA patients, especially in older patients. Aplastic anemia is a component of the collagen vascular syndrome called eosinophilic fasciitis. This severe, scleroderma-like disease is characterized by fibrosis of subcutaneous and fascial tissue, localized skin induration, eosinophilia, hypergammaglobulinemia, and an elevated erythrocyte sedimentation rate. The rheumatologic symptoms of fasciitis respond to corticosteroids, but the associated AA has a very poor prognosis. More rarely, AA has complicated systemic lupus erythematosus (SLE) and rheumatoid arthritis, but in many cases, the role of concomitant drug therapy is intricately. Rarely, AA can accompany Sjogren syndrome, multiple sclerosis, and immune thyroid disease. AA occasionally occurs in individuals with hypogammaglobulinemia or congenital immunodeficiency syndrome, thymoma or thymic hyperplasia.
Differential diagnosis and diagnosis by exclusion
The differential diagnosis for acquired aplastic anemia must include: hypoplastic acute leukemia, myelodisplastic syndrome (hypoplastic form), hairy cell leukemia and other lymphomas, bone marrow infiltration by solid tumors, osteomyelofibrosis, hypersplenism, severe megaloblasticanemia, anorexia nervosa, systemic lupus erythematosus, paroxysmal nocturnal hemoglobinuria, Fanconi anemia, congenital dyskeratosis, Shwachman-Diamond syndrome, isolated aplastic anemia ("pure red cell aplasia"), aplasia after chemo-or radiation therapy. 
Diagnostic workup for AA
-
a. Indication
The management for AA patients should be based on a therapy plan promptly made once the diagnosis has been confirmed. Treatment options must be identified and chosen with alacrity. The choice of therapy depends on the age of the patient, the severity of the disease, and the degree of the HLA-identity in a potential related or unrelated bone marrow donor (Figure 3 .The therapeutic algorithm for adult patients with Aplastic Anemia).
The interval between diagnosis and therapy, as studies have shown in cases of bone marrow transplantations, has a significant impact on the outcome. A therapy that is intended to cure will be indicated in three situations: symptomatic disease, severe disease or high risk disease. The patients with severe and very severe form of AA according to definition and the cases with non-severe AA but with severe cytopenia of at least one cell line which requires regular transfusions or with an increased risk for infections or bleeding invariably need definitive treatment. Also, progression of non-severe AA to severe AA is an indication for definitive therapy. Other situations are to be individually evaluated taking into consideration the course of the disease. 
b. Allogeneic Stem Cell Transplantation

Allogeneic Stem Cell Transplantation from an HLA-matched Sibling Donor
Since 2009, in our Hematology and Bone Marrow Transplantation Center, six patients diagnosed with severe acquired AA were treated with bone marrow transplant (BMT) from identical sibling donor. Three patients received this therapy as frontline treatment, the other three as a secondary therapy after failing combination immunosuppressive therapy (IST) with ATG and cyclosporine A (CsA). The characteristics of the patients are presented in Table 1 . Characteristics of patients treated with allogeneic HSCT from HLA identical sibling donor.
The median age at the time of BMT in this group of patients was 29 years (19-37 years). The conditioning regimen used was Cy200/ATG and the source of stem cells was the peripheral blood (PBSC) in all the six cases. Graft versus host disease (GvHD) prophylaxis was done with CsA and short course methotrexate (MTX). After 4-year median follow up, five of six patients are surviving.
Unfortunately, one patient died day + 16 after BMT due to severe infection. In the group of second-line therapy transplanted patients there was one case of graft failure at one year after BMT. The patient successfully received a second stem cell transplant. The second BMT conditioning regimen used in this case included fludarabine and total body irradiation (TBI). He had increasingly mixed chimerism at the time of graft rejection. The posttransplant immunosuppressive therapy with cyclosporine A was continued for about one year with slow dose tapering in all the cases. Remarkably, in both groups of patients there was no acute or chronic grade III/ IV GvHD.
Discussion:
Allogeneic bone marrow transplantation from an HLA-identical sibling donor is the standard of care in the following situations: as front-line therapy in cases of severe or very severe AA and age < 40 years and as second line therapy in cases of severe AA and age ˂ 50 years after the failure of at Transplantation for AA from an HLA-identical sibling donor has improved considerably over the years, with a 75% to 80% chance of long-term cure. A recent report from the EBMT of over 1500 patients confirmed that predictors of survival following BMT included matched sibling donor, age of less than 16 years, early transplant (time from diagnosis to transplant of less than 83 days) and a non-radiation conditioning regimen.
In our opinion, the most important aspects regarding best frontline therapy in AA patients are the age of the patient, the severity of the disease and the availability of an HLA-identical sibling donor. The cutoff age of 40 years for frontline BMT is controversial. The latest studies showed that the outcome of patients in the ranges of 20 to 30 years, 30 to 40 years and 40 to 50 years tend to be similar. However, even if the actual tendency is to shift the upper age limit to 50, we consider that upper limit of "young age" should be probably situated around age 30-35 and the disease severity and performance status should be taken into discussion. Obviously, response to allogeneic HSCT may be more rapid as compared to IST and may be preferable in a situation of an infected or transfusion refractory patient. Also, one study demonstrated that the outcome in patients undergoing transplantation after failing IST is worse than undergoing transplantation upfront.
However, retrospective analysis of our AA patients grafted from sibling matched donor showed that at 4 years median follow-up the mortality in both group of patients-first line BMT and second line BMT, was related only to transplant procedure (infection precociously occurred after BMT ). The meaning is that transplant related toxicity is a real concern.
In younger patients with AA, the standard conditioning proposed by the Working Party on SAA is cyclophosphamide 50 mg/kg x 4 + ATG (Cy200+ ATG). This regimen is nonmyeloablative and highly immunosuppressive to prevent graft rejection and GvHD. Because of the unsatisfactory results and in order to reduce transplant-related toxicity and improve survival of patients older than 30 years with sibling transplantation, the use of less cytotoxic but more immunosuppressive regimens was explored in several studies with encouraging results. Modified regimens included low dose cyclophosphamide (300 mg/m 2 x 4) in combination with fludarabine (30 mg/m 2 x 4) and ATG.
Also, according to the EBMT SAA working party retrospective analysis of 30 patients older than 30 years receiving reduced-intensity conditioning BMT, there was a higher probability of age-adjusted overall survival than the control group.
Based on these results, we consider that treating AA patients older than 30 years with up front allogeneic stem cell transplant from sibling HLA-matched donor using fludarabine -based conditioning may be a better option than with standard high dose cyclophosphamide conditioning In our group of patients the source of stem cells used in all the six grafts was only PBSC and as we can see there is no significant GvHD, acute or chronic.
Allogeneic Stem Cell Transplantation from an Unrelated Donor or Alternative Donor
In our medical center, in the same period of time as mentioned above, five patients diagnosed with severe AA and without a sibling donor received allogeneic stem cell transplant from unrelated HLA compatible donor. The characteristics of the patients are presented in Table 2 . Characteristics of patients treated with allogeneic HSCT from HLA Identical Unrelated Donor.
All unrelated transplant cases were with 10/10 allele matched donor. In all the cases unrelated transplantation was done as secondary therapy after failing immunosuppressive therapy Unrelated matched donor stem cell transplant may be taken into discussion in patients ˃ 40
years of age and with a good performance status if other treatments failed. As primary therapy, at present, there is no consensus. In young patients with very severe AA, unrelated BMT may be an option if a donor with a 10/10 match is available.
As in the case of sibling donor BMT, the patient age and performance status and the severity degree of the disease come into question for an unrelated transplantation. family matches, the actuarial survival rate was 45%, for patients with a single-locus mismatch, it was 25%, and for those with two to three loci mismatched, the survival rate was 11%.
According to an early EBMT report, the best results with unrelated or mismatched transplantation are seen in patients under the age of 21 years with disease duration of less than one year. Also, the International Bone Marrow Transplant Registry reported on a group of 318 alternative donor transplants in patients with SAA between 1988 and 1998, a 20% probability of graft failure and a survival probability at 5 years less than 40%. Most patients were young, heavily transfused and of poor performance status. however, more than 70% of patients acquired acute GvHD and over 50% developed chronic GvHD.
A recent meta-analysis of 18 heterogeneous trials evaluating the outcomes for patients who received unrelated donor transplants after failure to respond to IST, suggests that a good performance status and detailed HLA-matching contribute to improved survival.
A review of data from the EBMT analyzed 498 patients transplanted during 1990-2005. Only the year of BMT was associated with increased survival. Survival at 5 years increased from 38% before 1998 to 57% after 1998. Also after 1998, there was less graft failure, less acute and chronic GvHD. The authors suggest that these improvements in outcomes are due to better donor matching.
The outcome of unrelated donor transplants for SAA patients has improved not only due to better selection of HLA matched donors but also to significant changes in the conditioning regimen. was 73% for the group that received FCA and 79% for the group given the conditioning regimen including TBI. The most significant predictor of survival was the interval between diagnosis and transplantation, with 5-year survival rates of 87 and 55% for patients grafted within 2 years of diagnosis and more than 2 years after diagnosis, respectively. The overall cumulative incidence of acute GvHD grades II-IV and III-IV was 18% and 7%, respectively, with no difference between the two regimens. Chronic GvHD was recorded in 27% of the FCA group and 50% of the FCA-TBI group. This study confirmed that survival of patients with SAA treated with unrelated donor transplant has almost doubled in the past decade.
Even more than in standard sibling transplants, age is a crucial risk factor in unrelated transplants and probably more important than the level of match, conditioning regimen, or use of Tcell depletion.
EBMT recommends that treatment with alternative donor transplant should be adapted. In high mortality rate as it was resulted also from our experience in our center. More than half of our patients grafted from unrelated matched donor (three of five patients) died ( Table 3 . Clinical data of all Table 3 . Clinical data of all AA patients treated with alloHSCT in our center procedure and it is likely the poor results may be a consequence of this. However, alternative donor transplant is feasible. Alternative donor transplantation represents an option, especially for the young patient with very severe pancytopenia in whom immunosuppressive therapy has failed.
Late complication of bone marrow transplantation
Very late complications after transplantation include effects on growth and development, as well as on the function of endocrine, neurologic, and other organ systems. A high rate of secondary malignancies has been recorded after transplantation. For AA, among 320 patients who received transplantation in Seattle, four developed cancer, leading to a calculated risk seven times higher than for normal control participants. In a more recent update, 12 % of patients who survived more than two years after transplantation developed solid tumors. In an analysis of 700 transplanted patients with AA and Fanconi's anemia, the risk of developing a secondary malignancy was 14% at 20 years.
The hazard of lymphoid malignancies decreased with the time after transplantation, but the risk of solid tumours progressively increased. In general, the rates of secondary malignancies after BMT for AA and other diseases are similar. Immune events such as GvHD, treatment with ATG or monoclonal antibodies, and irradiation have been related to the development of secondary malignancies. It is important to be mentioned that in AA patients there is a significant risk of late malignancy independent of transplantation therapy. The risk of malignancy in the large registry of EBMT was equivalent for patients who received immunosuppression and those who underwent transplantation. Compared with general European population, the relative risk of malignancy was calculated at 5.15 for AA patients treated with immunosuppression and at 6.67 for patients receiving transplants.
c. Immunosuppressive therapy (IST)
Combined or Intensive Immunosuppressive Therapy (ATG plus CsA)
Immunosuppressive therapy is an effective alternative treatment for patients who are not candidates for BMT (Figure 3 . The therapeutic algorithm for adult patients with AA). Combination therapy with antithymocyte globulin (ATG) and Cyclosporine A (CsA) provides a response rate of 70-90%, and does significantly better than either agent alone with more complete response and better 5-year survival rates for responding patients.
Antithymocyte globulins are immunoglobulin preparations made from the sera of horses immunized against human thymocytes are the mainstays of current regimens. In Europe, the standard preparation of ATG has until recently been horse ATG (Lymphoglobuline) whereas in the United
States was and is still used ATGAM. All large European Cooperative studies have been done using horse ATG. The European preparation has been withdrawn from the market and replaced by rabbit ATG (Thymoglobuline) which was used for second or subsequent courses of IST ( Response rates to rabbit ATG are anticipated to be similar with horse ATG based on response rates to second courses of IST, the same immunogen and a similar production method binding to similar epitopes. There have been only limited studies using rabbit ATG for the first-line IST for AA.
The majority of the studies which examined rabbit ATG efficacy in the first line treatment for AA were non-randomized studies, which compared the results to historical controls and produced discrepant results. In contrast, a recently published randomized study comparing rabbit ATG with horse ATG showed that response rate and overall survival is significantly better with horse ATG.
The response rate after three months was 62% with horse ATG as compared to only 33% in the rabbit group. Total survival rate of 85% with horse ATG was superior to only 55% survival rate after treatment with rabbit ATG. However, the change from horse ATG to rabbit ATG was done in
Europe not on evidence-based reason, but due to lacking availability. Table 4 . Different Types of Antithymocyte Globulin.
ATG brand Cells used for immunization
The combination for the treatment of AA of an agent that lysis lymphocytes (ATG) with a drug that blocks lymphocyte function is rational and follows the observation that the more intense and prolonged the immunosuppression the higher success rate. CsA at a dose of 4-6mg/kg/day given for 12 months, in combination with ATG, was shown to be associated with a response rate of 71%.
Slow tapering of CsA (0.3-0.7 mg/kg/month) resulted in significantly reduced incidence of relapse (8%) versus rapid (>0.8 mg/kg/month) tapering (60%). The CsA blood level should be maintained between 150 and 250 μg/L, although there are no data on optimal levels. Infections are the principal cause of death during combination IST and having adverse effect on survival. In order to reduce infection related mortality, granulocytes stimulating growth factor (G-CSF) has been added to ATG and CsA. The current EBMT protocol recommends to use G-CSF only "on demand" during infectious episodes in neutropenic patients since there are some data reporting increased risk for clonal diseases after IST containing G-CSF.
In disease refractory to initial therapy with ATG and CsA, a repeat course as salvage regimen can produce a response rate of 30%.
Other immunosuppressants
Because half of patients with AA experience failure to IST, there have been many efforts to improve its efficacy by adding other agents. However, prospective studies conducted by the NIH group failed to show that the addition of mycophenolatemofetil or sirolimus to horse ATG/CsA results in improved overall response rate and reduced relapse rate.
Other immunosuppressants are used by some centers. High dose cyclophosphamide 45-50 mg/kg/day for 4 days without stem cell rescue is used by Johns Hopkins Group as treatment for patients with newly diagnosed AA with overall response rate claimed similar to that achieved with ATG + CsA. A prospective randomized study comparing this with ATG and CsA was terminated early because of excess deaths and fungal infections in the cyclophosphamide arm. Therefore, high dose cyclophosphamide without stem cell support is reserved for second or third line therapy.
Mycophenolatemofetil has been used in organ transplantation and autoimmune disorders. There are data showing that addition of this drug to ATG and CsA did not improve response nor reduce the relapse rate. Alemtuzumab treatment has been retrospectively investigated in a limited cohort of 35 heterogenous patients with a response rate of 60%.
Immunosuppressive therapy in older patients
For older patients, consideration for treatment should be preceded by medical assessment to exclude significant co-morbidities and requires discussion of the risk with the patient. Although there is no upper age limit for ATG administration, CsA alone may be considered for patients older than 60 years. The current EBMT treatment algorithm proposes to treat hospitalized patients who are severely ill by ATG and CsA if considered to be tolerable considering the co-morbidity profile, whereas to start newly diagnosed patients who are well and in an outpatient setting with CsA alone.
The outcomes for tolerability and toxicity, response and relapse rates were examined in 24 older patients (over 60 years of age) receiving IST. Seven patients received standard IST consisting of standard-dose ATG with or without CsA, and 17 patients received attenuated IST consisting of at least a 50% dose reduction of ATG with CsA or CsA alone. Six patients (25%) had early deaths, mostly due to infection. Early mortality appeared higher in the standard IST group, although this was not statistically significant (43 vs 18%; p = 0.4). The 2-year cumulative incidence of response was 42% (95% CI: 26-69%). Responders had significantly better survival than non-responders (p = 0.0002). The 3-year probability of OS was 49% (95% CI: 27-68%). Nine out of 14 evaluable patients in the attenuated IST group had durable responses to treatment. These data from this small cohort suggest that attenuated dose IST could be a reasonable treatment option for patients deemed unfit for standard-dose IST.
Late Complication of Immunosuppressive Therapy
Relapse after IST is common. About 30% or more of the patients that responded require reinstitution of IST. Most relapse respond to retreatment, and there is no clear relationship with worse survival. Late complication of IST therapy with great impact on survival is the development of clonal hematologic disorders, especially myelodysplasia and acute myeloid leukemia. In the National
Institutes of Health trials, the overall rate of clonal evolution is 12% to 15% at about one decade.
Over time, a minority of patients may develop a large clone of PNH and the haemolytic and thrombotic manifestations of PNH.
Immunosuppressive therapy for non-severe AA
There is only one prospective randomized trial of CsA alone or the combination of ATG/CsA treatments in patients with non-severe or moderate AA which showed that the outcomes of two groups of patients were comparable, with a 93% survival probability in the CsA group and 91% in the combination therapy group of patients.
Immunosuppressive therapy versus sibling matched donor BMT as frontline treatment
A recent analysis of outcomes from the EBMT comprising 2479 patients with SAA compared the survival after frontline treatment with IST versus BMT. Theresults showed a survival rate at 10 years of 73% in BMT recipients and 68% in those treated with IST (p = 0.002). It is important to mention that the frequency of secondary malignancy was much higher in the patients who received
IST alone (1.2%) compared with those who received BMT (0.1%).
d. Supportive care in Aplastic Anemia
Supportive management for AA patients include all the measures necessary to prevent the occurrence of the redoubtable complications of pancytopenia like bleeding, infections and iron Alloimmunization secondary to transfusions increases the risk for graft rejection and mortality after BMT. Blood products from a potential bone marrow donor (sibling or parent) should be avoided. The transfusion of leukocyte-depleted blood products is mandatory in AA patients. The 5% risk of graft rejection after transplantation in untransfused patients was increased to 15 % with receipt of 1 to 40 units and to more than 25% in more heavily transfused patients. These data are from a period before leukocyte depleted blood products were routinely used and it is likely that graft rejection would be lower with the reduced patient alloimmunization by using leukocyte-depleted blood products. Further studies are needed to confirm this.
The irradiation of blood products for aplastic anemia patients is recommended during and after treatment with ATG or alemtuzumab as long as patients are immunosuppressed with a reduced CD4/CD8 ratio or a minimum of 6 months after IST and in case of patients receiving allogeneic BMT. The main reasons for using irradiate blood products are to prevent allosensitization and transfusion-associated GvHD. Also, granulocyte and HLA-matched platelets concentrates must be irradiated.
CMV-negative blood products are given in case of patients undergoing allogeneic SCT where both the patient and donor are CMV negative. In general, there is no need for CMV-negative blood products when leukodepletion is applied.
Granulocyte concentrates are used as a temporary measure and are reserved for the cases of life-threatening infections and severe neutropenia.
Infections
There is very little data regarding infections prophylaxis and treatment in AA. The The use of G-CSF is recommended to be given for the treatment of infectious complications in AA patients. Because there are no guidelines and some studies have shown that prophylactic growth factors do not improve overall outcome, their use as infections prophylaxis is not advised.
Hospitalised patients with AA and severe neutropenia should ideally be cared for in isolation, in rooms with air filtration and should receive prophylactic antibiotics and antifungals.
Prevention of bacterial infections in severe neutropenic AA patients should be realised with a quinolone antibiotic or a combination of non-absorbable antibiotics such as neomycin and colistin depending on the local microbiological flora and rates of resistance.
Antifungal prophylaxis should be done in all patients with severe AA and prolonged neutropenia. Itraconazole, voriconazole or posaconazole appear to be more effective than fluconazole, as their activity against Aspergillus whereas fluconazole does not.
Antiviral prophylaxis and Pneumocystis jiroveci pneumonia (PJP) prophylaxis are not standardized. In case of allogeneic stem cell transplantation acyclovir and an anti -pneumocystis drug are routinely given. For patients treated with ATG the usage of acyclovir and PJP-prophylaxis is also a rule in many centers.
Iron chelation
It is now known that iron overload has a negative influence on the outcome of patients undergoing stem cell transplantation as well as a potential worsened effect on bone marrow function.
Therefore serum ferritin level above 1000 µg/L requires starting iron chelation therapy. On the other hand due to potential side effects of chelate therapy a risk-benefit analysis should be assessed for individual patients. When remission is achieved an iron overload can be treated with phlebotomy.
Psychological support
The diagnosis of Aplastic Anemia has an important psychological impact on the patients, most of them being at a young age with life expectancies. It is a serious condition with potential fatal complications, a chronic disease and a life changing experience. The patient and its family must be informed about the nature of the disease, treatment, prognostic and social impact. Some patients may need professional psychological support.
Androgens
Testosterone and synthetic anabolic steroids were introduced in the 1960s and at that moment Androgens were preponderantly used and still are for second-line treatment of AA patients, but there had been a limitation of their use due to side effects such as hirsutism or hepatic toxicity and also due to restrictions of their availability and manufacture. Occasionally, there may be observed a hematological improvement with a course of androgen therapy, may be more effective if combined with CsA.
Prognosis
In the modern era, indicators for prognosis, besides the classic initial blood counts of a patient with AA, are considered to be absolute reticulocyte count and absolute lymphocytes predicting a good response to immunosuppression and survival. The sturdiness of the platelet and reticulocyte response after immunosuppressive therapy also correlates with long-term survival. Clonal evolution is a poor prognostic factor, especially the acquisition of monosomy 7. The rate of spontaneous recovery is low, untreated severe AA being invariably fatal.
Moderate AA, in contrast with the severe form, has a good prognosis. Some patients may experience a hematologic recovery with no treatment.
Conclusions
The outcome of patients diagnosed with acquired Aplastic anemia has greatly improved over time. Age remains a major predictor of outcome for both BMT and immunosuppressive treatment. Early intervention is associated with a significantly superior outcome. Improved survival is seen both in patients grafted from a sibling matched donor, and those with a unrelated matched and alternative donor, suggesting that better supportive care and improved management of infections have an major impact on outcome.
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